The Sickle Cell Disease With Vaso-Occlusive Crisis drugs in development market research report provides comprehensive information on the therapeutics under development for Sickle Cell Disease With Vaso-Occlusive Crisis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Sickle Cell Disease With Vaso-Occlusive Crisis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Sickle Cell Disease With Vaso-Occlusive Crisis and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Sickle Cell Disease With Vaso-Occlusive Crisis by ten companies/universities/institutes. The top development phase for Sickle Cell Disease With Vaso-Occlusive Crisis is preclinical with four drugs in that stage. The Sickle Cell Disease With Vaso-Occlusive Crisis pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Sickle Cell Disease With Vaso-Occlusive Crisis pipeline products market are: GlycoMimetics, Pfizer and Asklepion Pharmaceuticals.

The key targets in the Sickle Cell Disease With Vaso-Occlusive Crisis pipeline products market include P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP), Prostaglandin G/H Synthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin Endoperoxide Synthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1), and Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1).

The key mechanisms of action in the Sickle Cell Disease With Vaso-Occlusive Crisis pipeline product include P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) Inhibitor with two drugs in Phase III. The Sickle Cell Disease With Vaso-Occlusive Crisis pipeline products include three routes of administration with the top ROA being Intravenous and four key molecule types in the Sickle Cell Disease With Vaso-Occlusive Crisis pipeline products market including Small Molecule, and Monoclonal Antibody.

Sickle Cell Disease With Vaso-Occlusive Crisis overview

Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration, and infection. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), acetaminophen, blood transfusion, and surgery.

For a complete picture of Sickle Cell Disease With Vaso-Occlusive Crisis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.